EBP and type 2 diabetes mellitus: A population study showed that individuals having a polymorphism (T-87C) of the FABP4 promoter at a C/EBP binding site have a lower expression level of FABP4, a lower plasma triglyceride level and reduced risk for both coronary heart disease and type 2 diabetes compared with individuals who were homozygous for the WT allele [31].